Palo Alto, Calif.-based pharma company Neumentum said today that it raised $6 million in a Series A round through the sale of convertible preferred stock.
The company plans to use its newly-acquired funds to advance two non-opioid drug products designed for pain management.
Get the full story at our sister site, Drug Delivery Business News.